Get back to living.

A customized approach
to CRT is the WiSETM choice.

What is Heart Failure?

Heart Failure is a serious condition in which the heart is unable to pump enough blood to meet the body’s demands. Heart Failure affects nearly 6 million people in the United States and more than 25 million globally. Some heart failure occurs due to conditions that cause the heart chambers to pump in a desynchronized manner, reducing the amount of blood pumped with each heartbeat. Cardiac Resynchronization Therapy (CRT) may be beneficial in these patients to synchronize the contraction of the right and left sides of the heart.


EBR understands one
solution can’t possibly
work for all patients.

Cardiac Resynchronization Therapy

Patients undergoing CRT receive an implantable pacemaker to synchronize the pumping of the heart chambers,  to improve the pumping action and in turn, reduce heart failure symptoms. CRT is an effective treatment for many patients, but limitations prevent some patients from benefiting.


You have
a choice.

WiSE Technology may
improve results and
reduce complications.

The WiSE choice

The WiSE Technology was developed to address the persistent limitations of current CRT systems and to provide a more customized, patient-specific solution.

The WiSE Technology utilizes a proprietary wireless system to deliver pacing stimulation directly to the inside of the left ventricle of the heart. This approach is designed to overcome limitations of existing CRT systems that deliver pacing stimulation to the outside of the left ventricle. Pacing from the inside of the left ventricle is believed to be more physiologic.5, 6 WiSE Technology is designed for more flexibility in pacing site selection to customize therapy for the individual.

Caution: Not commercially available in the United States

What makes the WiSE Technology
so unique?



Does not require a wire (lead) to stimulate the left ventricle. Designed to eliminate lead complications such as placement difficulty, unintended nerve stimulation, dislodgement, extraction and repositioning.



Delivers pacing stimulation directly to the inside of the left ventricle. Endocardial pacing is seen as more physiologic.5, 6, 7



Allows for tailored therapy to meet individual patient needs.  Endocardial pacing provides a broader selection of sites for stimulation, which may lead to better patient outcomes.8

Results are Clear

The SELECT-LV Study is a prospective, multi-center, non-randomized study of 34 patients who previously failed conventional CRT.* Patients were treated with the WiSE Technology at 6 leading clinical centers in Europe and evaluated at 30-days and 6-months post-procedure.8

*Includes patients considered to be at high risk for CRT upgrades.




successful placements




cardiac resynchronization at 1-month




persistent clinical benefits at 6-months

Our mission.

EBR Systems is driven to deliver superior treatment for millions of patients suffering from cardiac rhythm diseases by developing safe, clinically superior, cost-effective and reliable therapies using wireless cardiac stimulation.

Innovation starts at EBR.

EBR Systems, Inc. was founded in 2003 to develop an implantable system for wireless tissue stimulation, with an initial focus on addressing well-recognized shortcomings in treating heart failure with Cardiac Resynchronization Therapy (CRT). Based on a unique concept, the proprietary WiSE Technology is designed to eliminate the need for a lead to the left ventricle in CRT and the associated complications of that lead.

In the future, the company will extend this platform technology into other applications in the $11B cardiac rhythm management (CRM) market.

the team.

EBR Systems is proud to have an
exceptional team with a track record of success in developing and delivering innovative products to physicians and their patients.

Allan Will, Chairman of the Board, President  & CEO – Allan is an operating executive with extensive experience founding, funding, operating, and selling medical device companies.  Prior to EBR, he led negotiation of Ardian’s acquisition by Medtronic for over $800M.  Will was also founding Managing Director, Split Rock Partners and a Partner at St. Paul Venture Capital.  Previously, he was Founder, Chairman & CEO of The Foundry, co-founding 11 companies there including Ardian, Evalve (acquired by Abbott Laboratories for $450M) & Concentric Medical (acquired by Stryker for $135M).  Previously, Will was CEO of AneuRx, acquired by Medtronic, growing to >$150MM the year of launch.  In 1996 Will co-founded Adjacent Surgical, sold to GSII.  Previously, he was President & CEO of Devices for Vascular Intervention, growing the business to 550 employees, $100MM revenue run rate, and acquisition by Eli Lilly.  Will is an inventor on more than 30 issued patents, and has his M.S. in Management from MIT and his B.S. in Zoology from University of Maryland.  Will has also served on MIT’s Entrepreneurship Center Shareholders Board, on the University of Maryland President’s Committee on Innovation and Entrepreneurship and is a University of Maryland “Distinguished Alumnus”.  Will was the recipient of the Astia/Deloitte Leadership in Mentoring Award for mentoring women executives.

Allan Will 
Chairman, President & CEO

Rick Riley, COO, Co-Founder & Director – Rick has an extensive medical device development background with experience in a wide range of devices used in electrophysiology including pacemakers, defibrillators, CRM programmers, catheters, ablation energy technologies, and imaging and electro-mapping systems. He brings a strong management background to the team, including executive positions at Boston Scientific, Cardiac Pathways and Medtronic and as the Founding CEO of EBR Systems.  Riley is an inventor on more than 25 issued patents, and has his M.S. in Industrial and Management System Engineering from Arizona State University and his B.S. in Computer Science from University of Kansas.

Rick Riley
COO, Co-Founder &

Mark Cowan, Vice President of Engineering – Mark is an Electrical Engineer with 35 years of successful development experience in R&D leadership for medical instrumentation and systems.  He has completed devices from conception to market for both diagnostic and therapeutic use.  He brings a strong technical and management background to the team, including executive positions at Pharmasonics, Cardiometrics and Diasonics. Cowan is an inventor on more than 30 issued patents, and has his B.S. in Electrical Engineering from the University of the Pacific, Stockton.

Mark Cowan
Vice President of Engineering

Stephen O’Connor, Ph.D., Vice President of Clinical Marketing – Stephen has over 20 years of experience working in the fields of cardiac rhythm management and active implantable devices.  He brings to the team extensive experience in the areas of clinical research and training, regulatory affairs and business development, including positions at Boston Scientific, Cameron Health, Intervascular, CryoCath, Cyberonics, St. Jude, and Cardiac Pacemakers, Inc.. O’Connor received his B.Sc. in Physics from King’s College, University of London, and his M.Sc. and Ph.D. in Medical Electronics and Physics, from Medical College of St. Bartholomew’s Hospital, University of London.

Stephen O’Connor, Ph.D.
Vice President of Clinical Marketing

Andrew Shute, Vice President of Europe – Andrew has 20 years of medical device experience and has led the successful commercialization of new technologies and products working in the corporate, start-up and distributor settings.   He brings strong business, clinical training and sales management background to the team, including positions at St. Jude Medical, Endocardial Solutions and Getz Brothers. Shute received his B.S. from the University of Wollongong, Australia.  Shute previously held the position of Vice-Chairman of the Cardiac Rhythm Management section of the Association of British Healthcare Industries Ltd (ABHI).

Andrew Shute
Vice President of Europe

Mark Schwartz, Vice President of Clinical and Regulatory Affairs – Mark has over 20 years of experience in the medical device industry and has proven leadership in the design and execution of clinical studies.  He brings strong clinical study design and execution background to the team, including positions at The Sorin Group, Boston Scientific, Guidant, InControl and Intermedics. Schwartz is an inventor on more than 15 issued patents, and has his B.S. in Electrical Engineering from North Dakota State University and his M.S. in Biomedical Engineering from the University of Texas, Arlington.

Mark Schwartz
Vice President of Clinical & Regulatory Affairs

N. Parker Willis, Ph.D., Chief Technical Officer – Parker is an electrical engineer with extensive experience in signal processing applications and has worked in medical devices for 20 years, all in technical leadership capacities for development of novel technologies for cardiac electrophysiology.  He previously held senior positions at Boston Scientific and Cardiac Pathways.  Willis is an inventor on more than 28 issued patents, and has his B.Sc. in Electrical Engineering from the University of California, San Diego and his M.Sc. and Ph.D. from the University of Illinois Urbana Champaign.

N. Parker Willis, Ph.D.
Chief Technical Officer

Allan Will

President and CEO
EBR Systems, Inc.

Rick Riley

COO & Co-founder
EBR Systems, Inc.

Josh Baltzell

Venture Partner
Split Rock Partners

Thomas Fogarty, M.D.

Managing Director
Emergent Medical Partners

Stephen Mahle

Former Executive Vice President and President of Cardiac Rhythm Management Medtronic

David Milne

Managing Partner
SV Life Sciences

Doug Roeder

Delphi Ventures

William Starling

Managing Director
Synergy Life Science Partners